Sirukumab

From Wikipedia, the free encyclopedia
Sirukumab ?
Monoclonal antibody
Type Whole antibody
Source Human
Target IL6
Clinical data
Legal status ?
Identifiers
CAS number 1194585-53-9 N
ATC code None
Chemical data
Formula C6450H9926N1690O1998S46 
Mol. mass 144.6 kDa
 N (what is this?)  (verify)

Sirukumab (CNTO 136) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis.[1]

Sirukumab is currently under development by Johnson & Johnson's subsidiary Centocor.[2][3]

References

  1. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab". American Medical Association. 
  2. ↑ Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
  3. ↑ A Study of the Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy, clinicaltrials.gov
Monoclonal antibodies for the immune system
Immune system ("-l(i[m])-")
Human ("-limu-")
Mouse ("-limo-")
Chimeric ("-lixi-")
Humanized ("-lizu-")
Chimeric + humanized
("-lixizu-")
Interleukin ("-k(i[n])-")
Human ("-kinu-")
Humanized ("-kizu-", "-kinzu-")
Inflammatory lesions ("-les-")
Mouse ("-leso-")

M: LMC

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug (L3/4)


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.